Targeting harmful bacteria to improve treatment for gum disease
Official title: Evaluation of a microbiota-sparing therapeutic concept for periodontal disease, involving removal of pathogenic Porphyromonas and Fusobacterium
Funded at Texas A&m University Health Science Ctr · NIH-11222312 · Data updated 2026-11-12
This study is exploring a new way to treat gum disease by targeting specific harmful bacteria while keeping the good bacteria in your mouth healthy, which could lead to better results and fewer complications for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas A&m University Health Science Ctr NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project start | December 1, 2024 |
| Project end | January 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $27,583 |
| NIH project number | 3R21DE032798-01A1S1 |
| Project ID | NIH-11222312 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from chronic periodontal disease, particularly those with significant inflammation and bacterial infection.
✕Less likely to help
Patients who do not have periodontal disease or those with advanced stages requiring surgical intervention may not benefit from this research.
What this research studies
This research investigates a new approach to treating periodontal disease by focusing on the harmful bacteria Porphyromonas gingivalis and Fusobacterium nucleatum. The goal is to develop a narrow-spectrum therapeutic agent that selectively eliminates these pathogens without disrupting the beneficial oral microbiota. By targeting a specific enzyme involved in bacterial fatty acid synthesis, the research aims to reduce inflammation and promote a healthier oral environment. Patients may benefit from improved treatment outcomes and reduced risk of complications associated with periodontal disease.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for periodontal disease, reducing inflammation and preserving oral health.
How similar studies have gone: Previous research has shown promise in targeting specific bacterial pathogens in periodontal disease, suggesting that this approach could be effective.
Where this research is happening
-
Texas A&m University Health Science Ctr
College Station, United States Active
Researchers
- Principal investigator: Hurdle, Julian G — Texas A&m University Health Science Ctr
- Study coordinator: Hurdle, Julian G
Related research
Other NIH-funded projects on the same topics.
-
Targeting harmful bacteria to improve treatment for gum disease
This study is looking at a new way to treat gum disease by targeting specific harmful bacteria while keeping the good bacteria safe, which could help improve your gum health and lower the chances of losing teeth.
-
Precision nanomedicine to calm inflammation and protect bone in gum disease
A new, targeted nanomedicine approach aims to reduce gum inflammation and prevent bone loss in adults with periodontal disease.
-
Biofilm structure and its role in the start of gum disease
A researchers team will study how tiny communities of bacteria at the gumline interact with the mouth’s tissues to spark inflammation that leads from healthy gums to periodontal disease.
-
Diet, gut microbiome, and immune health in adults with type 2 diabetes
A study at Stanford is exploring how fermented foods and their molecules, like lactate, influence gut bacteria and the body's immune and inflammatory responses in adults with adult-onset diabetes.
-
Gut microbiome and Parkinson's disease: how gut bugs relate to symptoms and progression
A multi-year study will look at gut bacteria and related markers in people with Parkinson’s disease to understand how the gut-brain connection may influence symptoms and progression.
-
Gut-Brain Axis in Parkinson’s Disease: biomarkers and procedures to track progression
A patient-focused program to study how gut health and the brain interact in Parkinson’s disease using biomarkers and clinical procedures.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.